PRDM2 and glioma: The GBJ set-based analysis of the meta-analysis results found two of the 11 regions (16p13.3 containing RBFOX1 and 1p36.21 containing PRDM2) were significantly associated with female and male glioma risks, respectively, after adjusting for multiple testing (P16p13.3 = 0.003; P1p36.21 = 0.002; Table 2).